MaidihaoTesamorelin
Ordered Tesamorelin from Maidihao? Mail in a sample (US only) and let us test it for free.
Test my supplyMaidihao tesamorelin is dragged down by a severe April 2026 fill miss: 4.93 mg vs 10 mg (-51%) despite identity pass and 99.9% purity. Earlier tests had high purity and modest overfills, but missing batch IDs on two vials add uncertainty.
Corporate records tie Maidihao to a revoked Shenzhen trading company, while the storefront sits on a Shop910 stack built for cloaking and redirect rotation. The report maps borrowed sister-brand assets, placeholder support channels, and exposed payment rails.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Maidihao rows.
Cancel anytime
About Maidihao test results from Finnrick
Maidihao is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 3 peptides and 12 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Maidihao peptides in this dataset are Retatrutide (5 tests), Tesamorelin (4 tests) and Tirzepatide (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 12 recent tests.
Ordered Tesamorelin from Maidihao? Mail in a sample (US only) and let us test it for free.
Test my supply